ACT Capital Partners, L.P.’s Nuvation Bio NUVB Stock Holding History

ACT Capital Partners, L.P.’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.25M	Buy	+579,500	New	+$3.64M	2.11%	14

Other funds holding NUVB

Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

ACT Capital Partners, L.P.'s NUVB Position: Q3 2026 in Review

ACT Capital Partners, L.P. opened a new position in Nuvation Bio (NUVB) in Q3 2026: 579,500 shares worth $3.25M. The stake represents 2.11% of the portfolio and ranks #14 among its holdings.

87 funds tracked by Wall St. Rank hold NUVB as of Q3 2026.

ACT Capital Partners, L.P. held 579,500 shares of Nuvation Bio worth $3.25M as of Q3 2026.
Nuvation Bio was a new ACT Capital Partners, L.P. position in Q3 2026.
Nuvation Bio made up 2.11% of ACT Capital Partners, L.P.'s portfolio in Q3 2026, its #14 holding.
87 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2026.

Based on ACT Capital Partners, L.P.'s 13F filing for Q3 2026, filed 6 Nov 2026.